Genentech gets FDA approval for breast cancer drug

Roche's Genentech unit said Friday it received approval from the Food and Drug Administration for the breast cancer drug Perjeta for consumer use.

Roche could bring in sales as high as $1.6 billion in 2016 from the Perjeta injection, according to estimates compiled by Bloomberg.

Perjeta is designed to work with Roche's drug Herceptin and chemotherapy to attack breast cancer.

It is expected to be available within two weeks, though the FDA said production issues could affect long-term supplies.

alyssa bustamante protandim weightless ellen degeneres jcpenney yeardley love nba all star reserves rock center